Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | — | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 1 | — | — | — | 1 |
Drug common name | Galunisertib |
INN | galunisertib |
Description | LY-2157299 is a pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma. It has a role as a TGFbeta receptor antagonist and an antineoplastic agent. It is a member of quinolines, a pyrrolopyrazole, a member of methylpyridines, an aromatic amide and a monocarboxylic acid amide. |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1 |
PDB | — |
CAS-ID | 700874-72-2 |
RxCUI | — |
ChEMBL ID | CHEMBL2364611 |
ChEBI ID | — |
PubChem CID | 10090485 |
DrugBank | — |
UNII ID | 3OKH1W5LZE (ChemIDplus, GSRS) |